Bjørn Tore Gjertsen
Helse-Bergen HF
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Bjørn Tore Gjertsen as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:36 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06199557 · A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS PatientsHaukeland University Hospital · recruiting · Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes, Adult · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 10:36 UTC. The ranking covers the 200 most relevant of 25 PubMed records, and a shared surname and initials can bring in a namesake. All 25 on PubMed
- A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer.J Control Release · 2016337 citationsRCR 13.6
- Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris.Lancet · 1991276 citationsRCR 9.9
- 233 citationsRCR 6.5
- Cell therapy induced regeneration of severely atrophied mandibular bone in a clinical trial.Stem Cell Res Ther · 2018149 citationsRCR 8.4
- Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.Blood · 201793 citationsRCR 3.0
- Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.Leukemia · 202070 citationsRCR 3.5
- Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.J Hematol Oncol · 202170 citationsRCR 4.0
- Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.Blood Adv · 202167 citationsRCR 3.8
- Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).Eur J Haematol · 201561 citationsRCR 1.8
- 54 citationsRCR 1.7